Last reviewed · How we verify

NCT05965713

National Fully Remote Use of IpsiHand Device in Hemiparetic Stroke

Completed NA Last updated 15 December 2025
What this trial tests

NA trial testing Neurolutions IpsiHand System in Stroke in 109 participants. Completed in 30 October 2025.

Timeline
1 October 2023
Primary endpoint
12 September 2025
30 October 2025

Quick facts

Lead sponsorNeurolutions, Inc.
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment109
Start date1 October 2023
Primary completion12 September 2025
Estimated completion30 October 2025
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Neurolutions, Inc.

Who can join

Adults 18 to 85, any sex, with Stroke or Hemiparesis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this study is to define the efficacy of fully remote home-based BCI therapy in chronic hemiparetic subcortical stroke patients. A randomized controlled study using the integrated remote BCI system will be tested against standard exercise therapy to determine the efficacy of motor improvement in chronic stroke patients with an upper extremity hemiparesis. Specifically, the integrated BCI system will include 1) the remote screening and motor assessment system for the upper extremity and 2) the BCI-controlled robotic hand exoskeleton (i.e. IpsiHand).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Stroke

Currently open trials in the same condition.

Other Neurolutions, Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05965713.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing